Cargando…

Performance Evaluation of the Quantitative Point-of-Care LumiraDx d-Dimer Test

INTRODUCTION: Fibrin degradation product d-dimer can be a valuable indicator for venous thromboembolism (VTE). The use of d-dimer testing in primary care settings can be limited by restricted access to laboratory services. This performance evaluation compares a quantitative, point-of-care (POC) d-di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ellis, Jayne E., Johnston, Thomas W., Craig, David, Scribner, Anita, Simon, William, Kirstein, Judith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496146/ https://www.ncbi.nlm.nih.gov/pubmed/34618321 http://dx.doi.org/10.1007/s40119-021-00241-7

Ejemplares similares

Performance of the LumiraDx Microfluidic Immunofluorescence Point-of-Care SARS-CoV-2 Antigen Test in Asymptomatic Adults and Children
por: Drain, Paul, et al.
Publicado: (2021)

Performance of the LumiraDx Platform INR Test in an Anticoagulation Clinic Point-of-Care Setting Compared With an Established Laboratory Reference Method
por: Tait, Robert Campbell, et al.
Publicado: (2019)

Utilidad del test de antígenos SARS-COV-2 de LumiraDx™ en centros residenciales
por: Domínguez Fernández, Mercedes, et al.
Publicado: (2022)

Performance Evaluation of the Microfluidic Antigen LumiraDx SARS-CoV-2 and Flu A/B Test in Diagnosing COVID-19 and Influenza in Patients with Respiratory Symptoms
por: Ellis, Jayne E., et al.
Publicado: (2022)

Urgent care study of the LumiraDx SARS-CoV-2 Ag Test for rapid diagnosis of COVID-19
por: Gresh, Jared, et al.
Publicado: (2021)

Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™: An antigen-detecting point-of-care device for SARS-CoV-2
por: Krüger, Lisa J., et al.
Publicado: (2021)

Evaluation of the analytical sensitivity of ACON and LumiraDx SARS-CoV-2 rapid antigen tests using samples with presumed Omicron variant
por: Karon, Brad S., et al.
Publicado: (2023)

LumiraDX SARS-CoV-2 Antigen Test for Diagnosing Acute SARS-CoV-2 Infection: Critical Literature Review and Meta-Analysis
por: Lippi, Giuseppe, et al.
Publicado: (2022)

Rapid Antigen Test LumiraDx(TM) vs. Real Time Polymerase Chain Reaction for the Diagnosis of SARS-CoV-2 Infection: A Retrospective Cohort Study
por: Cattelan, Anna Maria, et al.
Publicado: (2022)

Extraction-Free Detection of SARS-CoV-2 Viral RNA Using LumiraDx’s RNA Star Complete Assay from Clinical Nasal Swabs Stored in a Novel Collection and Transport Medium
por: Daum, Luke T., et al.
Publicado: (2023)

Usefulness of the Lumiradx™ SARS-COV-2 antigen test in nursing home()
por: Domínguez Fernández, Mercedes, et al.
Publicado: (2022)

Preliminary results from the LUX‐Dx insertable cardiac monitor remote programming and performance (LUX‐Dx PERFORM) study
por: Stolen, Craig, et al.
Publicado: (2022)

A novel C-terminal DxRSDxE motif in ceramide synthases involved in dimer formation
por: Kim, Jiyoon L., et al.
Publicado: (2021)

DX centers
por: Munoz Merino, Elias
Publicado: (1994)

Diagnostic accuracy of the FebriDx host response point-of-care test in patients hospitalised with suspected COVID-19
por: Clark, Tristan W., et al.
Publicado: (2020)

Quench Performance and Field Quality of DX Dipoles for RHIC
por: Jain, A, et al.
Publicado: (1999)

PLANT-Dx: A Molecular Diagnostic for Point-of-Use Detection of Plant Pathogens
por: Verosloff, M., et al.
Publicado: (2019)

Utility of the FebriDx point‐of‐care test for rapid triage and identification of possible coronavirus disease 2019 (COVID‐19)
por: Karim, Nawazish, et al.
Publicado: (2020)

Evaluation of insertable cardiac monitor placement and safety in the LUX-Dx PERFORM study
por: Richards, M, et al.
Publicado: (2023)

Performance of the QIAstat-Dx Gastrointestinal Panel for Diagnosing Infectious Gastroenteritis
por: Boers, Stefan A., et al.
Publicado: (2020)

Interim evaluation of insertable cardiac monitor signal quality in the LUX-Dx PERFORM study
por: Richards, M, et al.
Publicado: (2023)

FebriDx host response point-of-care testing improves patient triage for coronavirus disease 2019 (COVID-19) in the emergency department
por: Mansbridge, Christopher T., et al.
Publicado: (2022)

FebriDx host response point-of-care testing improves patient triage for coronavirus disease 2019 (COVID-19) in the emergency department – ADDENDUM
por: Mansbridge, Christopher T., et al.
Publicado: (2022)

Point of Care D-Dimer Testing in the Emergency Department: A Bioequivalence Study
por: Perveen, Shuhana, et al.
Publicado: (2013)

Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study
por: Plasseraud, Kristen Meldi, et al.
Publicado: (2016)

DecisionDx-GBM Gene Expression Assay for Prognostic Testing in Glioblastoma Multiform
por: Allingham-Hawkins, Diane, et al.
Publicado: (2010)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)

Multicenter evaluation of the NeuMoDx™ SARS-CoV-2 Test
por: Mostafa, Heba H., et al.
Publicado: (2020)

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
por: Iles, Kathleen, et al.
Publicado: (2022)

The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting
por: Choi, Joseph Do Woong, et al.
Publicado: (2022)

Performance evaluation of the QIAstat-Dx® Respiratory SARS-CoV-2 Panel
por: Lebourgeois, Samuel, et al.
Publicado: (2021)

DE/DX TPC in cosmic data
por: Chevalier, L
Publicado: (1989)

Esterilidad femenina Dx. y Tx. /
por: Jiménez Jácome, José Alfredo
Publicado: (1987)

Calibration of the ALEPH dE/dx
por: Assmann, R W, et al.
Publicado: (1994)

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

Economic Evaluation of FebriDx®: A Novel Rapid, Point-of-Care Test for Differentiation of Viral versus Bacterial Acute Respiratory Infection in the United States
por: Dick, Katherine, et al.
Publicado: (2021)

Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer
por: Whitney, Jon, et al.
Publicado: (2018)

Test Performance and Potential Clinical Utility of the GenMark Dx ePlex Blood Culture Identification Gram-Negative Panel
por: McCarty, T. P., et al.
Publicado: (2023)

Comments on Point of Care D-Dimer Testing in the Emergency Department: A Bioequivalence Study
por: Ekelund, Suzanne, et al.
Publicado: (2014)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
por: Malam, Yogeshkumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ngbajomjbsa0fmme08hbv1urnv